Kilybayev Sanat Serikovich
PhD in Biological Sciences
Specialist in virus cultivation, development of means and methods for specific prevention of viral infectious diseases in animals, as well as organization of production of preventive biopreparations.
Author of about 20 scientific works, including 5 articles in international journals with impact factor, indexed in Web of Science and Scopus, h-index: 3; co-author of 1 monograph; holder of 4 patents in the Republic of Kazakhstan; co-author of 4 regulatory documents (NTD) on vaccine preparations.
He participated in more than 10 trainings and courses. In 2024, he completed advanced training at LLP “NNC OOI” on “Biosafety, Epidemiology, and Epizootology of Especially Dangerous Infections of I-II Pathogenicity Groups” with a total of 480 hours in Almaty, Republic of Kazakhstan.
Laboratory projects:
| 0112РК00300 | Development of technology for producing an inactivated vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS), 2012–2014. |
| 0113РК00948 | Development of technology for producing a vaccine against camel pox, 2013–2015. |
| 1755/ГФ4 | Monitoring and genetic characterization of viruses causing infectious diseases in pigs in Kazakhstan, 2015–2017. |
| 1072/ГФ4 | Development of technology for producing a bivalent inactivated vaccine against European and North American genotypes of PRRS, 2017–2019. |
| AP08855665 | Development of technology for producing an inactivated vaccine against camel pox, 2021–2023. |
| AP19676490 | Bluetongue: main vectors, distribution area, and genetic characterization of the virus circulating in Kazakhstan, and implementation of specific preventive measures, 2023–2025. |
| Government assignments | Services for ensuring biological safety in the scientific field. |
Main Tasks of the Laboratory:
- Deposition, preservation, and maintenance of microorganism strains in a biologically active state;
- Supplementation of the collection with new isolates and strains;
- Primary study of the biological properties of newly received isolates and strains of microorganisms, and documentation of museum specimens;
- Periodic verification of biological activity and refreshment of production and control strain matrices required for the manufacture and quality control of vaccines and diagnostic preparations;
- Deposition of strains of especially dangerous pathogens for patent purposes;
- Provision of virus strains and biomass to other institute departments for research purposes;
- Ensuring the preservation of especially dangerous pathogen strains and maintaining biosafety while working with them to prevent accidental release of hazardous biological agents into the environment.
Main Achievements of the Laboratory:
- A collection of strains of exotic viral disease pathogens and especially dangerous infections occurring among animals and birds in neighboring countries and in the Republic of Kazakhstan;
- Creation of virological boxes with biosafety level II+, allowing work with microorganisms of pathogenicity groups I and II;
- Construction of a special pathogen storage facility with a three-level protection system and installation of an autonomous power station;
- In 2004, the collection became part of the World Federation for Culture Collections;
- Laboratory staff have published over 90 articles since 1997, including 21 in international journals; developed 20 regulatory and technical documents (NTD) on vaccines; obtained 59 patents for inventions;
- Laboratory staff participated in approximately 20 projects under the NTP RK, 4 projects via MNTC, 3 contracts with DTRA of the US Department of Defense, and attended 4 conferences held in the USA, Russia, and Kyrgyzstan.
Innovative Developments of the Laboratory:
- Development of 20 sets of scientific and technical documentation for preventive preparations;
- Obtained 59 patents for inventions;
- A collection of strains of exotic viral disease pathogens and especially dangerous infections found among animals and birds in neighboring countries and Kazakhstan;
- Development and implementation of technology for producing live camel pox vaccine;
- Development of a biological model to assess immunogenicity of vaccines against COVID-19;
- Development of virus inactivation parameters for production of inactivated camel pox vaccine;
- Annual production of camel pox vaccine under state order.
Key Publications of the Laboratory: